VVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency – FDA decision expected ...

- Adjusted earnings per share (EPS) surged 24.7% year over year to $0.91 for Q2 2025, topping analyst expectations by $0.13 (non-GAAP). - Despite higher earnings, revenue (GAAP) grew just 2.7% to ...

(NYSE: FLS) (“Flowserve”), a leading provider of flow control products and services for the global infrastructure markets, today announced it has terminated its previously announced merger agreement ...

Clippard’s latest innovation – its Isolation Valves with Hit & Hold Circuitry - provide design engineers and machine builders with a reliable, ...